Direct-to-consumer advertising of prescription medicines in the USA isthe fastest-growing promotional segment for the drug industry, according to the pharmaceutical consulting firm Scott-Levin. In its DTC Advertising 1996 report, the company noted that:
- pharmaceutical companies spent nearly $600 million in 1996 on DTC advertising of prescription drugs, up 56% from 1995;
- 10 companies accounted for more than 90% of all DTC ads in 1996, and these were Glaxo Wellcome, Johnson & Johnson, Schering-Plough, Merck & Co, Pfizer, Bristol-Myers Squibb, Wyeth Ayerst, Hoechst Marion Roussel, Bayer and SmithKline Beecham;
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze